Company Encyclopedia
View More
name
Achieve Life Sciences
ACHV.US
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
1.946 T
ACHV.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lake Street Keeps Their Buy Rating on Achieve Life Sciences (ACHV)

    Lake Street analyst Thomas Flaten has reaffirmed a Buy rating on Achieve Life Sciences (ACHV) with a price target of $11.00. Flaten, a 5-star analyst with an 18.0% average return and a 54.15% success rate, focuses on the Healthcare sector. The current analyst consensus for Achieve Life Sciences is a Strong Buy, with an average price target of $14.60.

    Tip Ranks·
    US
    ACHV
    -2.05%
    Tip Ranks·
    US
    ACHV
    -2.05%

    Positive Outlook for Achieve Life Sciences: Buy Rating Backed by Promising Regulatory Progress and Market Potential

    JonesTrading analyst Justin Walsh has reiterated a Buy rating for Achieve Life Sciences (ACHV) stock, citing promising regulatory progress and market potential for its drug cytisinicline, which targets smoking cessation. The FDA has set a PDUFA target action date for the drug, which has shown a favorable safety profile. Additionally, cytisinicline has received a National Priority Voucher from the FDA, indicating potential for expedited review. H.C. Wainwright also maintains a Buy rating with a $12.00 price target, reflecting confidence in the company's future.

    Tip Ranks·
    US
    ACHV
    -2.05%
    Tip Ranks·
    US
    ACHV
    -2.05%

    Achieve Life Sciences: Advancements in Cytisinicline Propel Buy Rating Amid Regulatory Milestones and Clinical Success

    H.C. Wainwright analyst Brandon Folkes has maintained a Buy rating on Achieve Life Sciences (ACHV) stock, citing significant regulatory milestones for cytisinicline, including FDA acceptance of its New Drug Application and a Commissioner’s National Priority Voucher. These developments could lead to a U.S. launch by late 2026 and expedite market entry within 18-24 months. New data also shows cytisinicline's effectiveness in smoking cessation for COPD patients. Lake Street also reiterated a Buy rating with an $11.00 price target.

    Tip Ranks·
    US
    ACHV
    -2.05%
    Tip Ranks·
    US
    ACHV
    -2.05%

    Achieve Life Sciences Q3 net loss widens

    Achieve Life Sciences reported a widened net loss for Q3, missing analyst expectations with an EPS of -$0.28 against a consensus of -$0.26. The company’s net loss was $14.44 million, exceeding the expected $12.20 million. The FDA accepted the NDA for cytisinicline, with a PDUFA date set for June 20, 2026. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $13.00, reflecting a potential upside of 62.1% from its recent closing price of $4.93.

    Reuters·
    US
    ACHV
    -2.05%
    Reuters·
    US
    ACHV
    -2.05%

    Achieve Life Sciences | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ACHV
    -2.05%
    LB filings·
    US
    ACHV
    -2.05%
    © 2025 Longbridge｜Disclaimer